Conversely, another pilot study reported that while AR-V7 expression was detected in all 16 included patients with clinically localized high-risk PCa, prior to receiving neoadjuvant ABI + bicalutamide + ADT, its level of expression was not correlated with pathologic response [23]. This evidence concerns the gene AR and posterior cortical atrophy.